Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
Blue curve MMWR spacer

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: Type 508 Accommodation and the title of the report in the subject line of e-mail.

Fatal Yellow Fever in a Traveler Returning from Amazonas, Brazil, 2002

Yellow fever (YF) is a mosquitoborne viral disease that has caused deaths in U.S. and European travelers to sub-Saharan Africa and tropical South America (1--5). Although no specific treatment exists for YF and the case-fatality rate for severe YF is approximately 20%, an effective vaccine is available (6). This report describes a case of fatal YF in an unvaccinated traveler who had returned from a 6-day fishing trip on the Rio Negro west of Manaus in the state of Amazonas, Brazil. Because information from some commercial outfitters and travel agents might underestimate health risks, health-care providers and travelers should review vaccination and other traveler's health recommendations from public health agencies.

On return from Brazil on March 10, 2002, a previously healthy man aged 47 years from Texas presented to an emergency department (ED) with a 4-day history of crampy abdominal pain and a 1-day history of fever of 102.8° F (39.3° C) and severe headache. At the ED, he received symptomatic treatment and doxycyline for a possible rickettsial disease and was discharged. His fever and headache worsened, and on March 12 he was hospitalized for intractable vomiting.

On admission, physical examination revealed an ill-appearing, febrile man. Laboratory tests documented leukopenia (2,300/mm3 [normal: 4,800--10,800/mm3]), anemia (hemoglobin 10.5 g/dL [normal: 14--18 g/dL]), thrombocytopenia (36,000/mm3 [normal: 150,000--450,000/mm3]), abnormal coagulation (prothrombin time: 29 seconds [normal: 10.5--13.0 seconds] and INR 6.3), renal failure (creatinine: 5.5 mg/dL [normal: 0.6--1.0 mg/dL] and blood urea nitrogen: 65 mg/dL [normal: 6--20 mg/dL]), and liver failure (ALT: 7,600 U/L [normal: 30--65 U/L], AST: 13,700 U/L [normal: 15--37 U/L], and bilirubin: 3.3 mg/dL [normal: 0--1.0 mg/dL]). The patient was presumptively treated for malaria. Bacterial cultures of blood, urine, and cerebrospinal fluid showed no growth, and a malaria smear of peripheral blood was negative. Three days after admission, the patient developed shock, seizures, and excessive bleeding at venipuncture sites; he died the following day.

Tests performed at CDC on serum samples collected on the second day of illness were negative for IgM and IgG antibody to South American arboviruses (i.e., YF, dengue, St. Louis encephalitis, and Venezuelan equine encephalomyelitis viruses); serum samples collected on days 3--7 also were negative for IgM and IgG antibody to YF virus. Serum specimens collected on days 4, 5, and 7 of illness and a postmortem liver sample were positive for YF virus RNA by RT-TaqMAN PCR tests. Virus isolation was attempted by inoculation of serum samples onto Vero and AP-61 cells in tissue culture, and by inoculation of postmortem plasma onto Vero cells in tissue culture and intracerebrally into suckling mice. No virus was recovered.

Histopathologic examination of a postmortem percutaneous needle sample of the liver demonstrated massive acidophilic hepatocellular necrosis with minimal inflammation. Immunohistochemistry (IHC) tests using a cross-reactive, polyclonal flavivirus antibody and a polyclonal YF-virus--specific antibody were positive. IHC tests for New World arenaviruses (Machupo, Guanarito, and Sabia viruses), spotted fever rickettsiae, dengue virus, and Leptospira spp. were negative. A postmortem serum sample was negative for IgM and IgG antibody to Leptospira spp. and New World arenaviruses, and negative for Machupo virus by ELISA antigen capture. A blood sample collected on day 2 was negative for malaria by PCR test.

The deceased traveler was one of 15 U.S. citizens who visited the Amazon as part of a fishing trip. The patient slept aboard an air-conditioned fishing boat and wore DEET-impregnated clothing while fishing. Before traveling to the Amazon, the traveler had not received medical consultation, YF vaccine, or malaria prophylaxis. Information on the outfitter's website stated, "The International medical community suggests yellow fever and malaria prophylaxis for the Amazon region. This is not a requirement to enter Brazil, but merely a suggestion." A brochure from the group's travel agent stated, "We do not suggest any inoculations of any kind for this trip....But to make sure you are worry free, consult with your personal physician."

The 15 U.S. citizens living aboard this fishing boat (including the patient) were interviewed or investigated by the Texas Department of Health. Other than the patient, none reported febrile illnesses. Eight (53%) were appropriately vaccinated for YF according to World Health Organization (WHO) guidelines (i.e., within the preceding 10 years and >10 days before arrival in Manaus). Of the seven that were not appropriately vaccinated, one had received YF vaccine 11 years earlier, one had been vaccinated 5 days before arrival in Manaus, and one was unsure whether he had been vaccinated in the military >30 years earlier. Of the four persons (including the patient) who were never vaccinated, three stated that they had been "unconcerned" about the risk for YF. Three (20%) of the 15 reported taking malaria prophylaxis.

Reported by: P Hall, MD, M Fojtasek, MD, J Pettigrove, MD, Corpus Christi Medical Center--Bay Area; N Sisley, MD, Corpus Christi-Nueces County Public Health District, Corpus Christi, Texas. J Perdue, K Hendricks, MD, S Stanley, MD, D Perrotta, PhD, Texas Dept of Health. AA Marfin, MD, GL Campbell, MD, RS Lanciotti, PhD, LR Petersen, MD, Div of Vector-Borne Infectious Diseases; PE Rollin, MD, TG Ksiazek, PhD, Div of Viral and Rickettsial Diseases; MS Cetron, MD, D Sharp, MD, Div of Global Migration and Quarantine, National Center for Infectious Diseases; KG Julian, MD, EIS Officer, CDC.

Editorial Note:

This case represents the third reported YF death in a U.S. citizen following travel to the Amazon region since 1996 (1,2). YF can initially manifest as fever, headache, myalgias, arthralgias, epigastric pain, or vomiting (6). Illness can progress to liver and renal failure, and thrombocytopenia and abnormal coagulation can cause hemorrhagic symptoms and signs. Definitive diagnosis is made by viral culture of blood or tissue specimens or by identification of YF virus antigen or nucleic acid in tissues (especially liver) using IHC, ELISA antigen capture, or PCR tests. Although antibodies are not always present in the first week of illness, detection of YF-specific IgM antibody by capture ELISA with confirmation of >4-fold rise in neutralizing antibody titers between acute- and convalescent-phase serum samples also is diagnostic.

On returning home, viremic travelers can establish new foci of YF transmission where susceptible vectors are present. The geographic range of Aedes aegypti, a mosquito that transmits YF virus among humans, includes the southern United States. Patients with suspected or confirmed YF should be isolated from contact with mosquitoes during at least the first 5 days of illness, and local or state health departments must be notified immediately (7). YF is one of three diseases (along with cholera and plague) designated by the International Health Regulations as internationally quarantinable and requires international reporting of all suspected and confirmed cases within 24 hours (8).

Commercial outfitters and travel agents should ensure that health information provided to travelers is consistent with CDC and WHO YF vaccination and malaria prophylaxis recommendations. Undervaccination of travelers at risk for YF might be an increasing problem. Using a mathematical model based on U.S. arrivals to countries where YF transmission occurs and on YF vaccine doses sold to U.S. civilians, overall coverage among U.S. travelers to regions where YF is endemic might have declined 50% from 1992 to 1998 (9). The degree to which inaccurate health information contributes to apparently decreasing coverage is unknown.

Because of the severity of YF illness, the potential for epidemics, and the availability of an efficacious vaccine, CDC recommends vaccination of persons aged >9 months traveling to nonurban areas where YF is endemic (i.e., sub-Saharan Africa and tropical South America, including Amazonas states in Brazil and Venezuela). To allow for an adequate immune response, vaccination should be completed >10 days before travel. Some countries, other than the United States, require YF vaccination for travelers returning from countries where YF is endemic and may impose quarantine if the traveler does not have official vaccination documentation or a written medical waiver. Although recent reports described occurrence of severe systemic illness potentially related to recent YF vaccination (10), the rarity of these events does not warrant changes in YF vaccination recommendations. Before international travel, persons should review CDC recommendations ( for prevention of vectorborne and other travel-related diseases.


  1. McFarland JM, Baddour LM, Nelson JE, et al. Imported yellow fever in a United States citizen. Clin Infect Dis 1997;25:1143--7.
  2. CDC. Fatal yellow fever in a traveler returning from Venezuela, 1999. MMWR 2000;49:303--5.
  3. Barros MLB, Boecken G. Jungle yellow fever in the central Amazon. Lancet 1996;348:969--70.
  4. World Health Organization. Yellow fever, 1998--1999. Wkly Epidem Rec 2000;75:322--8.
  5. World Health Organization. Outbreak news: imported case of yellow fever, Belgium (update). Wkly Epidem Rec 2001;76:365.
  6. Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, Pennsylvania: WB Saunders, 1999:815--79.
  7. Chin J, ed. Control of communicable diseases manual. 17th ed. Washington, DC: American Public Health Association, 2000.
  8. World Health Organization. International health regulations (1969): 3rd annotated ed. Geneva, Switzerland: World Health Organization, 1983.
  9. Monath TP, Cetron MS. Preventing yellow fever in travelers to the tropics. Clin Infec Dis (in press).
  10. CDC. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996--2001. MMWR 2001;50:643--5.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to

Page converted: 4/18/2002


Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A


Department of Health
and Human Services

This page last reviewed 4/18/2002